A Study of E7130 in Participants With Solid Tumors

Summary

The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with solid tumors.

Timeline

Start

2018-02-05

Primary completion

2024-12-27

Completion

2024-12-27

Publications

• Matsubara N, Saijo K, Shimizu Y, Okano S, Nakano K, Nishio N, Otsuka T, Kuno H, Miura T, Kubota T, Ikezawa H, Umetsu Y, Ito K, Apfel A, Ye Y, Honma Y. First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck. Cancer Sci. 2026 May 27. doi: 10.1111/cas.70420. Online ahead of print.
• Doi T, Matsubara N, Naito Y, Kuboki Y, Harano K, Ono M, Urasaki T, Ohmoto A, Kawanai T, Hisai T, Ikezawa H, Shiba S, Ito K, Semba T, Asano O, Takahashi S. First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part. Cancer. 2023 Aug 1;129(15):2348-2359. doi: 10.1002/cncr.34788. Epub 2023 Apr 20.

Drugs

Indications